PNO1

Summary

PNO1 (partner of NOB1 homolog, HGNC:32790) is a protein-coding gene on chromosome 2p14, encoding RNA-binding protein PNO1 (Q9NRX1). Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. It is a selective cancer dependency (DepMap: 88.7% of cell lines).

Enables RNA binding activity. Involved in ribosomal small subunit biogenesis. Located in nucleolus and nucleoplasm. Part of small-subunit processome.

Source: NCBI Gene 56902 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 48 total
• Cancer dependency (DepMap): dependent in 88.7% of screened cell lines
• MANE Select transcript: NM_020143

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32790
Approved symbol	PNO1
Name	partner of NOB1 homolog
Location	2p14
Locus type	gene with protein product
Status	Approved
Aliases	RRP20
Ensembl gene	ENSG00000115946
Ensembl biotype	protein_coding
OMIM	618710
Entrez	56902

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 2 protein_coding, 1 nonsense_mediated_decay, 1 retained_intron

ENST00000263657, ENST00000430742, ENST00000488728, ENST00000867856

RefSeq mRNA: 3 — MANE Select: NM_020143 NM_001329916, NM_001329917, NM_020143

CCDS: CCDS1885

Canonical transcript exons

ENST00000263657 — 7 exons

Exon	Start	End
ENSE00000758770	68158380	68158529
ENSE00000758774	68162265	68162325
ENSE00000758776	68162546	68162663
ENSE00000758778	68173347	68173417
ENSE00001006437	68157888	68158141
ENSE00001006439	68174735	68176238
ENSE00003503153	68161683	68161766

Expression profiles

Bgee: expression breadth ubiquitous, 291 present calls, max score 99.92.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 34.7228 / max 233.3963, expressed in 1820 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
20669	27.9666	1819
20668	6.7562	1679

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	99.92	gold quality
tendon of biceps brachii	UBERON:0008188	98.90	silver quality
olfactory bulb	UBERON:0002264	97.13	silver quality
diaphragm	UBERON:0001103	96.48	gold quality
type B pancreatic cell	CL:0000169	95.30	silver quality
medial globus pallidus	UBERON:0002477	95.08	silver quality
globus pallidus	UBERON:0001875	93.08	silver quality
mucosa of urinary bladder	UBERON:0001259	91.46	gold quality
oviduct epithelium	UBERON:0004804	91.45	gold quality
cartilage tissue	UBERON:0002418	91.13	gold quality
triceps brachii	UBERON:0001509	90.73	gold quality
heart right ventricle	UBERON:0002080	90.54	gold quality
tongue squamous epithelium	UBERON:0006919	90.10	silver quality
superficial temporal artery	UBERON:0001614	89.61	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	89.24	gold quality
biceps brachii	UBERON:0001507	89.03	gold quality
tendon	UBERON:0000043	88.93	gold quality
corpus epididymis	UBERON:0004359	88.77	gold quality
cauda epididymis	UBERON:0004360	88.45	gold quality
pericardium	UBERON:0002407	87.91	gold quality
male germ cell	CL:0000015	87.82	gold quality
subthalamic nucleus	UBERON:0001906	87.59	gold quality
gluteal muscle	UBERON:0002000	87.39	gold quality
lateral nuclear group of thalamus	UBERON:0002736	87.30	silver quality
epithelium of nasopharynx	UBERON:0001951	87.29	gold quality
cervix epithelium	UBERON:0004801	87.28	gold quality
oral cavity	UBERON:0000167	87.06	gold quality
fallopian tube	UBERON:0003889	87.03	gold quality
gastrocnemius	UBERON:0001388	87.00	gold quality
amniotic fluid	UBERON:0000173	86.98	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

52 targeting PNO1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-577	99.78	69.13	2479
HSA-MIR-4658	99.77	64.94	514
HSA-MIR-7856-5P	99.75	69.99	2901
HSA-MIR-33A-3P	99.70	70.27	3362
HSA-MIR-1283	99.69	72.42	3009
HSA-MIR-3942-3P	99.57	69.03	2854
HSA-MIR-510-3P	99.54	70.06	2965
HSA-MIR-6832-3P	99.52	70.44	1726
HSA-MIR-3171	99.49	69.06	776
HSA-MIR-4251	99.40	69.19	3363
HSA-MIR-377-3P	99.37	70.18	1905
HSA-MIR-4652-3P	99.33	70.02	2742
HSA-MIR-3064-5P	99.26	66.13	1497
HSA-MIR-3085-3P	99.26	66.16	1490
HSA-MIR-6504-5P	99.26	65.95	1487
HSA-MIR-149-5P	99.25	67.16	1315
HSA-MIR-548L	99.06	70.90	2560
HSA-MIR-1207-3P	98.99	66.22	1532
HSA-MIR-4738-3P	98.98	67.98	1846
HSA-MIR-3145-3P	98.85	69.07	2031
HSA-MIR-487A-5P	98.85	69.37	993

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 88.7% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 11)

• A detailed characterization of PNO1 organization and its interaction with NOB1. (PMID:30176151)
• High PNO1 expression is associated with colorectal cancer. (PMID:30862720)
• Importance of PNO1 for growth and survival of urinary bladder carcinoma: Role in core-regulatory circuitry. (PMID:31800162)
• PON1 polymorphisms can predict generalized anxiety and depressed mood in patients with multiple chemical sensitivity. (PMID:33728967)
• Knockdown of PNO1 inhibits esophageal cancer progression. (PMID:33864661)
• PNO1 regulates autophagy and apoptosis of hepatocellular carcinoma via the MAPK signaling pathway. (PMID:34050137)
• Ribosome assembly factor PNO1 is associated with progression and promotes tumorigenesis in triplenegative breast cancer. (PMID:35445733)
• PNO1 inhibits autophagy-mediated ferroptosis by GSH metabolic reprogramming in hepatocellular carcinoma. (PMID:36446769)
• Inhibition of ribosome assembly factor PNO1 by CRISPR/Cas9 technique suppresses lung adenocarcinoma and Notch pathway: Clinical application. (PMID:36625087)
• Partner of NOB1 homolog transcriptionally activated by E2F transcription factor 1 promotes the malignant progression and inhibits ferroptosis of pancreatic cancer. (PMID:37929351)
• PNO1 promotes the progression of osteosarcoma via TGF-beta and YAP/TAZ pathway. (PMID:38071381)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	pno1	ENSDARG00000008502
mus_musculus	Pno1	ENSMUSG00000020116
rattus_norvegicus	Pno1	ENSRNOG00000005524
rattus_norvegicus		ENSRNOG00000066543
drosophila_melanogaster	l(1)G0004	FBGN0027334
caenorhabditis_elegans		WBGENE00013144

Protein

Protein identifiers

RNA-binding protein PNO1 — Q9NRX1 (reviewed: Q9NRX1)

Alternative names: Partner of NOB1

All UniProt accessions (2): Q9NRX1, F8WBJ6

UniProt curated annotations — full annotation on UniProt →

Function. Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. During the assembly of the SSU processome in the nucleolus, many ribosome biogenesis factors, an RNA chaperone and ribosomal proteins associate with the nascent pre-rRNA and work in concert to generate RNA folding, modifications, rearrangements and cleavage as well as targeted degradation of pre-ribosomal RNA by the RNA exosome. Positively regulates dimethylation of two adjacent adenosines in the loop of a conserved hairpin near the 3’-end of 18S rRNA.

Subunit / interactions. Part of the small subunit (SSU) processome, composed of more than 70 proteins and the RNA chaperone small nucleolar RNA (snoRNA) U3.

Subcellular location. Nucleus. Nucleolus.

Tissue specificity. Expressed in liver, lung, spleen and kidney. Weakly expressed in thymus, testis and ovary. Weakly or not expressed in heart, brain, skeletal muscle, placenta, pancreas, prostate, small intestine, colon and peripheral blood leukocytes.

Similarity. Belongs to the PNO1 family.

RefSeq proteins (3): NP_001316845, NP_001316846, NP_064528* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004087	KH_dom	Domain
IPR036612	KH_dom_type_1_sf	Homologous_superfamily
IPR055211	KH_PNO1_2nd	Domain
IPR055212	KH-I_PNO1_first	Domain

Pfam: PF22891

UniProt features (29 total): helix 12, strand 7, turn 2, compositionally biased region 2, sequence variant 2, chain 1, domain 1, region of interest 1, modified residue 1

Structure

Experimental structures (PDB)

22 structures.

PDB	Method	Resolution (Å)
7MQA	ELECTRON MICROSCOPY	2.7
6ZXE	ELECTRON MICROSCOPY	3
7WTU	ELECTRON MICROSCOPY	3
7WTZ	ELECTRON MICROSCOPY	3
6ZUO	ELECTRON MICROSCOPY	3.1
7WTT	ELECTRON MICROSCOPY	3.1
7WTX	ELECTRON MICROSCOPY	3.1
6ZXD	ELECTRON MICROSCOPY	3.2
7WTS	ELECTRON MICROSCOPY	3.2
7WTW	ELECTRON MICROSCOPY	3.2
7WU0	ELECTRON MICROSCOPY	3.3
6G5I	ELECTRON MICROSCOPY	3.5
7WTV	ELECTRON MICROSCOPY	3.5
6G18	ELECTRON MICROSCOPY	3.6
7MQ8	ELECTRON MICROSCOPY	3.6
8ZDD	ELECTRON MICROSCOPY	3.7
8ZDC	ELECTRON MICROSCOPY	3.8
7MQ9	ELECTRON MICROSCOPY	3.87
6G4S	ELECTRON MICROSCOPY	4
6G51	ELECTRON MICROSCOPY	4.1
6G4W	ELECTRON MICROSCOPY	4.5
6G53	ELECTRON MICROSCOPY	4.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NRX1-F1	77.91	0.47

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 1

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-6790901	rRNA modification in the nucleus and cytosol
R-HSA-6791226	Major pathway of rRNA processing in the nucleolus and cytosol

MSigDB gene sets: 231 (showing top): ELVIDGE_HYPOXIA_DN, GOBP_RIBOSOME_BIOGENESIS, BORCZUK_MALIGNANT_MESOTHELIOMA_UP, chr2p14, GOBP_MATURATION_OF_SSU_RRNA, PUJANA_CHEK2_PCC_NETWORK, WEI_MYCN_TARGETS_WITH_E_BOX, SCHUHMACHER_MYC_TARGETS_UP, MILI_PSEUDOPODIA_HAPTOTAXIS_UP, GOBP_RIBOSOMAL_SMALL_SUBUNIT_BIOGENESIS, GENTILE_UV_HIGH_DOSE_DN, GENTILE_UV_RESPONSE_CLUSTER_D5, GARY_CD5_TARGETS_DN, DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_UP, DODD_NASOPHARYNGEAL_CARCINOMA_UP

GO Biological Process (1): ribosomal small subunit biogenesis (GO:0042274)

GO Molecular Function (3): RNA binding (GO:0003723), nucleic acid binding (GO:0003676), protein binding (GO:0005515)

GO Cellular Component (5): nucleus (GO:0005634), nucleoplasm (GO:0005654), nucleolus (GO:0005730), cytosol (GO:0005829), small-subunit processome (GO:0032040)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
rRNA processing in the nucleus and cytosol	2

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
nuclear lumen	2
cellular anatomical structure	2
ribonucleoprotein complex biogenesis	1
ribosome biogenesis	1
nucleic acid binding	1
intracellular membrane-bounded organelle	1
intracellular membraneless organelle	1
cytoplasm	1
nucleolus	1
preribosome	1
t-UTP complex	1
nuclear protein-containing complex	1

Protein interactions and networks

STRING

2113 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PNO1	NOB1	Q9ULX3	946
PNO1	LTV1	Q96GA3	916
PNO1	BYSL	Q13895	905
PNO1	RIOK2	Q9BVS4	902
PNO1	TSR1	Q2NL82	883
PNO1	RIOK1	Q9BRS2	832
PNO1	RRP12	Q5JTH9	822
PNO1	RCL1	Q9Y2P8	764
PNO1	BMS1	Q14692	738
PNO1	NOP14	P78316	735
PNO1	UTP20	O75691	717
PNO1	UTP14A	Q9BVJ6	704
PNO1	NAT10	Q9H0A0	658
PNO1	RSL1D1	O76021	638
PNO1	KRR1	Q13601	617

IntAct

95 interactions, top by confidence:

A	B	Type	Score
PNO1	NOB1	psi-mi:“MI:0915”(physical association)	0.740
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
RIOK1	PRMT5	psi-mi:“MI:0914”(association)	0.710
PICK1	PNO1	psi-mi:“MI:0915”(physical association)	0.560
PNO1	JPH3	psi-mi:“MI:0915”(physical association)	0.560
UTP14A	DHX37	psi-mi:“MI:0914”(association)	0.530
DDX21	MED19	psi-mi:“MI:2364”(proximity)	0.480
PNO1	HNRNPA1L2	psi-mi:“MI:0915”(physical association)	0.400
PNO1	HNRNPA2B1	psi-mi:“MI:0915”(physical association)	0.400
PNO1	HNRNPA1	psi-mi:“MI:0915”(physical association)	0.400
CSNK1E	PNO1	psi-mi:“MI:0915”(physical association)	0.370
PNO1	FRZB	psi-mi:“MI:0915”(physical association)	0.370
PNO1	PDPK1	psi-mi:“MI:0915”(physical association)	0.370
Naa50	WDR46	psi-mi:“MI:0914”(association)	0.350
RPL10	RPS6	psi-mi:“MI:0914”(association)	0.350
Srp72		psi-mi:“MI:0914”(association)	0.350
Gspt1	MRPL27	psi-mi:“MI:0914”(association)	0.350
Rrbp1	PIPSL	psi-mi:“MI:0914”(association)	0.350
NCBP3	ALYREF	psi-mi:“MI:0914”(association)	0.350
HNRNPU		psi-mi:“MI:0914”(association)	0.350
MYC	TARS3	psi-mi:“MI:0914”(association)	0.350
NPM1	RPSA	psi-mi:“MI:0914”(association)	0.350
Eif3e	RPSA	psi-mi:“MI:0914”(association)	0.350
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
EGLN3	FAM168B	psi-mi:“MI:0914”(association)	0.350
NP	KPNA6	psi-mi:“MI:0914”(association)	0.350

BioGRID (175): PNO1 (Affinity Capture-MS), PNO1 (Affinity Capture-MS), PNO1 (Affinity Capture-MS), COMTD1 (Affinity Capture-MS), UTP14A (Affinity Capture-MS), UTP14C (Affinity Capture-MS), MTMR3 (Affinity Capture-MS), NOB1 (Affinity Capture-MS), PNO1 (Affinity Capture-MS), CSNK1E (Co-fractionation), LRRC47 (Co-fractionation), NOB1 (Co-fractionation), NOC3L (Co-fractionation), PNO1 (Co-fractionation), PNO1 (Co-fractionation)

ESM2 similar proteins: A3RCV9, B8ARK7, O45551, O60341, O61955, O74743, P07260, P08487, P10686, P19174, P41229, P41230, P48598, P49870, P56570, P78954, P98150, Q09305, Q10NQ9, Q21693, Q22888, Q2NKY8, Q38JA7, Q5BJI6, Q5BJS0, Q5R607, Q5XI06, Q5ZI74, Q62077, Q6DCK1, Q6YYZ1, Q6Z690, Q6ZQ88, Q75AV8, Q7L2E3, Q7M753, Q7XKC0, Q7XWV4, Q80Y84, Q8LI34

Diamond homologs: A7RP64, G0S3T2, O14044, O18216, P0CO46, P0CO47, Q0UWT7, Q1DQZ5, Q29IG6, Q2UMG1, Q4IN63, Q4PMC9, Q4WNG7, Q54K66, Q57885, Q5ACM4, Q5B0Z5, Q5F414, Q626C1, Q6BJ75, Q6C7G0, Q6CUA5, Q6DDB9, Q6FMB3, Q6VBQ6, Q6VBQ8, Q6VEU3, Q753C6, Q7YRD0, Q8AVH4, Q99216, Q9CPS7, Q9NRX1, Q9VR89, A0A0H3NM73, A0PQE7, A0QVQ5, A1AG69, A1KMC6, A2RGH2

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 110 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
SARS-CoV-1 modulates host translation machinery	6	25.4×	8e-06
Eukaryotic Translation Initiation	5	21.1×	1e-04
Cap-dependent Translation Initiation	5	21.1×	1e-04
rRNA modification in the nucleus and cytosol	8	20.5×	4e-07
rRNA processing in the nucleus and cytosol	9	19.8×	9e-08
Major pathway of rRNA processing in the nucleolus and cytosol	23	19.4×	2e-21
Eukaryotic Translation Elongation	5	19.1×	2e-04
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S	5	18.6×	2e-04

GO biological processes:

GO term	Partners	Fold	FDR
maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)	7	50.7×	1e-08
ribosomal small subunit biogenesis	11	26.9×	2e-10
rRNA processing	11	16.8×	1e-08
mRNA export from nucleus	5	15.9×	2e-03
cytoplasmic translation	7	13.9×	1e-04
translation	7	7.7×	4e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

48 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	37
Likely benign	1
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1170 predictions. Top by Δscore:

Variant	Effect	Δscore
2:68158051:A:T	donor_gain	1.0000
2:68158085:G:GT	donor_gain	1.0000
2:68158491:A:G	donor_gain	1.0000
2:68158514:G:GT	donor_gain	1.0000
2:68158515:A:T	donor_gain	1.0000
2:68158525:TCAGG:T	donor_gain	1.0000
2:68158528:GG:G	donor_gain	1.0000
2:68158529:GG:G	donor_gain	1.0000
2:68158530:G:C	donor_loss	1.0000
2:68158530:G:GG	donor_gain	1.0000
2:68158531:T:A	donor_loss	1.0000
2:68161679:ACAG:A	acceptor_loss	1.0000
2:68161680:CA:C	acceptor_loss	1.0000
2:68161681:A:AG	acceptor_gain	1.0000
2:68161682:G:GT	acceptor_gain	1.0000
2:68161682:GA:G	acceptor_gain	1.0000
2:68161682:GAC:G	acceptor_gain	1.0000
2:68161682:GACT:G	acceptor_gain	1.0000
2:68161682:GACTT:G	acceptor_gain	1.0000
2:68161766:GGTG:G	donor_loss	1.0000
2:68161767:G:GG	donor_gain	1.0000
2:68161768:T:A	donor_loss	1.0000
2:68162322:GATG:G	donor_gain	1.0000
2:68162544:A:AG	acceptor_gain	1.0000
2:68162545:G:GA	acceptor_gain	1.0000
2:68162545:GTT:G	acceptor_gain	1.0000
2:68162545:GTTA:G	acceptor_gain	1.0000
2:68162545:GTTAA:G	acceptor_gain	1.0000
2:68162659:GATGT:G	donor_gain	1.0000
2:68162660:ATGT:A	donor_gain	1.0000

AlphaMissense

1647 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:68158411:T:A	V80D	1.000
2:68158423:G:C	R84T	1.000
2:68158424:A:C	R84S	1.000
2:68158424:A:T	R84S	1.000
2:68158435:T:C	L88S	1.000
2:68158446:T:A	W92R	1.000
2:68158446:T:C	W92R	1.000
2:68158448:G:C	W92C	1.000
2:68158448:G:T	W92C	1.000
2:68161752:G:C	G143R	1.000
2:68161753:G:A	G143D	1.000
2:68161753:G:T	G143V	1.000
2:68161755:T:C	F144L	1.000
2:68161756:T:C	F144S	1.000
2:68161757:T:A	F144L	1.000
2:68161757:T:G	F144L	1.000
2:68162268:G:C	A149P	1.000
2:68162269:C:A	A149E	1.000
2:68162275:C:A	A151D	1.000
2:68162284:G:T	R154M	1.000
2:68162310:T:C	F163L	1.000
2:68162311:T:C	F163S	1.000
2:68162312:T:A	F163L	1.000
2:68162312:T:G	F163L	1.000
2:68162546:T:A	V168D	1.000
2:68162550:A:C	K169N	1.000
2:68162550:A:T	K169N	1.000
2:68162576:G:C	R178T	1.000
2:68162576:G:T	R178M	1.000
2:68162577:G:C	R178S	1.000

dbSNP variants (sampled 300 via entrez): RS1000084481 (2:68165228 G>A), RS1000115082 (2:68163040 C>A), RS1000372833 (2:68157296 C>A,T), RS1001070748 (2:68170679 C>T), RS1001127133 (2:68164295 G>T), RS1001317224 (2:68158590 G>A), RS1001368711 (2:68164013 A>G), RS1001645567 (2:68155997 G>A), RS1001735574 (2:68168131 G>A), RS1001789105 (2:68161407 G>A,C), RS1001865826 (2:68159649 C>T), RS1001991512 (2:68156222 C>T), RS1002042261 (2:68164457 C>T), RS1002078467 (2:68168410 G>C), RS1002354939 (2:68167733 T>A,C)

Disease associations

OMIM: gene MIM:618710 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

47 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression	3
bisphenol A	affects expression, decreases expression	2
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	2
Air Pollutants	increases abundance, increases oxidation, increases expression, affects cotreatment	2
Arsenic	affects methylation, affects cotreatment, increases abundance, increases expression	2
Tretinoin	decreases expression	2
Cyclosporine	increases expression	2
Aflatoxin B1	increases expression, affects cotreatment, decreases expression	2
aristolochic acid I	decreases expression	1
afuresertib	decreases expression	1
FR900359	affects phosphorylation	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
deoxynivalenol	increases expression	1
arsenite	affects binding, increases reaction	1
afimoxifene	decreases reaction, increases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
cylindrospermopsin	increases expression	1
perfluoro-n-nonanoic acid	increases expression	1
abrine	decreases expression, increases expression	1
Bortezomib	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Bexarotene	decreases expression	1
Acrolein	affects cotreatment, increases oxidation, increases abundance	1
Cisplatin	decreases expression	1
Estradiol	increases expression	1
Estrogens	decreases reaction, increases expression	1
Ethyl Methanesulfonate	decreases expression	1
Ivermectin	decreases expression	1
Manganese	affects cotreatment, increases abundance, increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.